GLP1_NEW

Liraglutide and metformin injection

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

LIRAMETF_SC

Trials: 4
Participants in these arms: 65

Doses in this pooled treatment

Effects across outcomes

Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.

Condition	Outcome	Window	Versus	Effect (95% CrI)	SUCRA
Type 2 diabetes (adults)	HbA1c change	weeks 20 to 36 (target week 26)	Placebo	MD -1.03 (-1.96 to 0.27)	0.60
Type 2 diabetes (adults)	Level 2 or 3 hypoglycemia (participants)	longest follow-up	Placebo	HR 1.35 (0.24 to 6.60)	0.55
Type 2 diabetes (adults)	Systolic blood pressure change	weeks 20 to 36 (target week 26)	Placebo	MD -6.60 (-10.47 to -2.59)	0.93
Type 2 diabetes (adults)	Discontinuation due to adverse events	longest follow-up	Placebo	HR 0.64 (0.01 to 47.82)	0.62
Type 2 diabetes (adults)	Diarrhea	longest follow-up	Placebo	HR 0.68 (0.06 to 3.92)	0.71
Type 2 diabetes (adults)	Discontinuation due to gastrointestinal adverse events	longest follow-up	Placebo	HR 0.74 (0.01 to 46.77)	0.55
Polycystic ovary syndrome	Nausea	longest follow-up	Placebo	HR 6.24 (2.08 to 17.45)	0.17
Polycystic ovary syndrome	Vomiting	longest follow-up	Placebo	HR 8.42 (1.01 to 63.07)	0.21
Polycystic ovary syndrome	Diarrhea	longest follow-up	Placebo	HR 4.09 (1.02 to 18.58)	0.08

Trials

S003022
2018 · 60 randomized · 12 weeks
NCT02909933
Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of Obesity
2015 · 30 randomized · 12 weeks
S003108
2012 · 24 weeks
NCT01911468
Short-term Combined Treatment With Liraglutide and Metformin Leads to Significant Weight Loss in Obese Women With Polycystic Ovary Syndrome and Previous Poor Response to Metformin
2011 · 40 randomized · 12 weeks